HUTCHMED (CHINA) LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 290 GBX | -4.61% |
|
+7.41% | +2.47% |
| Apr. 26 | EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug | MT |
| Apr. 26 | Hutchmed notes CHMP's positive opinion for fruiquintinib approval | AN |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3,356 | 4,555 | 6,141 | 2,698 | 3,074 | 3,084 | - | - |
| Enterprise Value (EV) 1 | 3,165 | 4,147 | 5,156 | 2,085 | 2,870 | 2,885 | 2,778 | 2,841 |
| P/E ratio | -31.5 x | -34.9 x | -28.7 x | -7.43 x | 30 x | -26.7 x | 561 x | 31.8 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 16.4 x | 20 x | 17.2 x | 6.33 x | 3.67 x | 4.53 x | 3.69 x | 3.02 x |
| EV / Revenue | 15.4 x | 18.2 x | 14.5 x | 4.89 x | 3.42 x | 4.23 x | 3.32 x | 2.78 x |
| EV / EBITDA | -22.4 x | -21.8 x | -16.1 x | -5.23 x | 108 x | -19.2 x | -53.1 x | 143 x |
| EV / FCF | -35.4 x | - | -23.4 x | -6.83 x | 15.4 x | -14.1 x | -111 x | 50.7 x |
| FCF Yield | -2.83% | - | -4.28% | -14.6% | 6.5% | -7.1% | -0.9% | 1.97% |
| Price to Book | 11.7 x | 9.46 x | 6.28 x | 4.52 x | 4.29 x | 1.56 x | 1.54 x | 1.26 x |
| Nbr of stocks (in thousands) | 665,965 | 724,205 | 856,470 | 845,074 | 853,410 | 853,644 | - | - |
| Reference price 2 | 5.039 | 6.290 | 7.170 | 3.193 | 3.602 | 3.612 | 3.612 | 3.612 |
| Announcement Date | 3/3/20 | 3/4/21 | 3/3/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 204.9 | 228 | 356.1 | 426.4 | 838 | 681.4 | 835.8 | 1,022 |
| EBITDA 1 | -141.4 | -190.6 | -321.1 | -399 | 26.58 | -150.1 | -52.35 | 19.9 |
| EBIT 1 | -146.4 | -196.7 | -328.3 | -407.7 | 18.38 | -153.1 | -43.91 | 32.47 |
| Operating Margin | -71.45% | -86.27% | -92.19% | -95.61% | 2.19% | -22.47% | -5.25% | 3.18% |
| Earnings before Tax (EBT) 1 | -141.1 | -189.7 | -215.7 | -410.4 | 58.31 | -142.4 | -34.55 | 52.25 |
| Net income 1 | -106 | -125.7 | -194.6 | -360.8 | 100.8 | -108.9 | -6.19 | 85.38 |
| Net margin | -51.75% | -55.15% | -54.66% | -84.62% | 12.03% | -15.98% | -0.74% | 8.36% |
| EPS 2 | -0.1600 | -0.1800 | -0.2500 | -0.4300 | 0.1200 | -0.1355 | 0.006440 | 0.1137 |
| Free Cash Flow 1 | -89.48 | - | -220.6 | -305.3 | 186.6 | -204.7 | -24.98 | 56.04 |
| FCF margin | -43.67% | - | -61.95% | -71.59% | 22.27% | -30.04% | -2.99% | 5.48% |
| FCF Conversion (EBITDA) | - | - | - | - | 702.15% | - | - | 281.67% |
| FCF Conversion (Net income) | - | - | - | - | 185.2% | - | - | 65.64% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/3/20 | 3/4/21 | 3/3/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2019 S2 | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 | 2025 S1 | 2025 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 102.7 | 106.8 | 121.2 | 157.4 | 198.8 | 202 | 224.4 | 532.9 | 305.1 | 321.9 | 349.3 | 404.9 | 414.8 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | -78.16 | -118.5 | -143.7 | -184.6 | -196.8 | -210.9 | 111.7 | -93.28 | -65.2 | -79.6 | -61.44 | -67.52 |
| Operating Margin | - | -73.21% | -97.77% | -91.34% | -92.86% | -97.38% | -94.02% | 20.95% | -30.57% | -20.25% | -22.79% | -15.18% | -16.28% |
| Earnings before Tax (EBT) 1 | - | -76.58 | -113.2 | -140.4 | -75.29 | -200.6 | -209.8 | - | -78.78 | -39.7 | -103.1 | - | - |
| Net income 1 | - | -49.69 | -76.04 | -102.4 | -92.25 | -162.9 | -198 | - | -67.77 | -52.6 | -64.3 | - | - |
| Net margin | - | -46.55% | -62.73% | -65.07% | -46.41% | -80.61% | -88.24% | - | -22.21% | -16.34% | -18.41% | - | - |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/3/20 | 7/30/20 | 3/4/21 | 7/28/21 | 3/3/22 | 8/1/22 | 2/28/23 | 7/31/23 | 2/28/24 | - | - | - | - |
1USD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 190 | 408 | 985 | 613 | 204 | 199 | 306 | 243 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -89.5 | - | -221 | -305 | 187 | -205 | -25 | 56 |
| ROE (net income / shareholders' equity) | -31.3% | -32.6% | -26.5% | -45.2% | 13.8% | -13.6% | -3.02% | 11% |
| ROA (Net income/ Total Assets) | -21.3% | -21.1% | -18.6% | -30% | 7.88% | -9.66% | -3.88% | 3.85% |
| Assets 1 | 498.6 | 594.6 | 1,048 | 1,201 | 1,280 | 1,127 | 159.5 | 2,217 |
| Book Value Per Share 2 | 0.4300 | 0.6700 | 1.140 | 0.7100 | 0.8400 | 2.310 | 2.350 | 2.860 |
| Cash Flow per Share 2 | -0.1200 | -0.0900 | -0.2600 | -0.3200 | 0.2500 | -0.1300 | -0.0300 | 0.0900 |
| Capex 1 | 8.57 | 7.95 | 16.4 | 36.7 | 32.6 | 26.1 | 24.2 | 27.5 |
| Capex / Sales | 4.18% | 3.49% | 4.61% | 8.6% | 3.89% | 3.83% | 2.89% | 2.7% |
| Announcement Date | 3/3/20 | 3/4/21 | 3/3/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.612
USD
Average target price
5.412
USD
Spread / Average Target
+49.84%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +2.47% | 3.08B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- HCM Stock
- Financials HUTCHMED (China) Limited
